Replies to post #331877 on Avid Bioservices Inc (CDMO)

[biopharm]

Avid Bioservices CDMO will receive much licensing fees from their IP assets and the question remains what incentives John Springs Stafford received for his role

Thanks for the update on all patents mentioning Bavituximab etc because it has DOUBLED since I last checked and I was only researching all the top Big Pharma patents that would require licenses

A third party test, to test MANY drugs to verify which BPs have PS Targeting drugs would be coming and that will surprise all

Some more reminders how Omeros poachinh from Merck

In the end, it is BP vs BP and all will require PS Targeting and hedge fund vs hedge fund as all hedge funds will require CDMO as they have Apple

More IIS will be getting this information

_____

Danielle Aldredge

Sr Scientist II at Omeros Corporation
Seattle, Washington
Biotechnology76

Experience

Sr Scientist II
Omeros Corporation
March 2019 – Present 7 months

Senior Scientist
Merck

_______________

Sara Goldstein ties to Univ of PA knowledge of PS Targeting also now at Omeros and Univ Of PA knows well of PS Targeting Biomarkers